SciSparc Quantum Program & Neuroplastogen Patent Spark 30% Stock Surge

Company overview

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company headquartered in Tel Aviv, Israel. Founded in August 2004, SciSparc focuses on developing and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company operates through two segments: Drug Development, which advances both FDA-approved compounds and New Chemical Entities, and Online Sales, which offers hemp-based consumer products, including gummies, oil capsules, and creams, in the United States.

Corporate structure

SciSparc employs between 11 and 50 professionals across research and development, manufacturing, clinical and regulatory affairs, and commercial operations. The board and executive team include:

• Amitay Weiss, founder, board member since August 2020 and CEO from August 2020 to January 2021
• Oz Adler, Chief Financial Officer since April 2018
• Dr. Dalia Zuloff-Shani, Chief Technology Officer since February 2016
• Fadi Shrem, President since January 2022
• Meir Revach and Nili Sidi, independent directors since August 2020

Management collectively has experience in biochemistry, pharmacology, capital markets, and corporate governance.

Cannabinoid pharmaceuticals by R+R Medicinals

Developments and news

On September 29, 2025, SciSparc announced the launch of a quantum computing initiative to model three-dimensional protein structures, establishing a wholly owned Israeli subsidiary and collaborating with structural biology and quantum algorithm experts. On November 20, 2025, the company filed an Israeli patent application with Neurothera Labs for a non-hallucinogenic neuroplastogen treatment targeting depression. Earlier, on November 4, 2025, SciSparc withdrew its Form F-4 Registration Statement, reflecting a reassessment of planned securities offerings. The company is also recruiting a Computational Chemistry Project Manager for a hybrid role in Tel Aviv to lead quantum-enabled molecular simulation projects.

Financial and strategic analysis

As of November 26, 2025, SciSparc’s shares closed at USD 3.19 on the Nasdaq, a 30.74% increase from the prior session, with a trading volume of 6,429,099 shares. The 52-week range spans USD 1.75 to USD 37.59, and the market capitalization is approximately USD 4 million. For the twelve months ended September 30, 2025, SciSparc reported USD 1.31 million in revenue and a net loss of USD 6.48 million. Valuation metrics include a price-to-sales ratio of 1.43 and an enterprise value-to-revenue multiple of 4.95. Strategic partnerships and proprietary endocannabinoid technologies are integral to the company’s focus on addressing indications with limited therapeutic options.

Market position and industry context

The global legal cannabis market was valued at USD 69.78 billion in 2024 and is projected to reach USD 216.76 billion by 2033, reflecting a 13.49% compound annual growth rate from 2025 to 2033. SciSparc’s pipeline includes SCI-110 for Tourette syndrome and obstructive sleep apnea, SCI-160 for pain, and SCI-210 for autism spectrum disorder and epilepsy, targeting central nervous system disorders that currently lack effective treatments. Evolving U.S. state regulations have facilitated the expansion of medical cannabis operators into adjacent hemp and recreational markets, influencing supply, competition, and regulatory focus for pharmaceutical-grade cannabinoid developers.

tl;dr

On September 29, 2025, SciSparc launched a quantum computing-based 3D protein modeling program. On November 20, 2025, it filed a patent for a non-hallucinogenic neuroplastogen treatment for depression. The November 4, 2025, withdrawal of its Form F-4 reflects a shift in capital-raising plans. Shares rose 30.74% to USD 3.19 on November 26, 2025. Strategic partnerships and key hires aim to advance the cannabinoid pipeline in a market projected to grow at a 13.49% CAGR through 2033.